




10 July Day 1 Session 1	08:25 - 13:00
Welcome Kurt Stenmark	08:25 - 08:30
Digital Health Technology Advancements & Implementation at FDA, FNIH, Pharma & Academia to Optimise Clinical Trial Designs & Innovative Endpoints in PH Chairs: Regulators TBD Panellists: Veronica Franco & Harry Rowland	
CDER & CDRH DCN initiatives Regulator speaker TBD	08:30 - 08:50
FDA CDER (DCN) DHT initiatives: adults & paediatric Christine Garnett	08:50 - 09:10
FNIH, Pharma & Academia Pioneering of Digital Endpoints	09:10 - 10:40
FNIH initiative to further the COA development of DHT endpoints Regulator speaker TBD	09:10 - 09:20
Taking the plunge with actigraphy: USA & China (The water's warmer than you think) Peter Fernandes	09:20 - 09:30
Application of the cardiomems in the artisan trial Yan Liu	09:30 - 10:00
Panel discussion & debate	10:00 - 10:40
Break	10:40 - 11:00
Novel Trial Designs The Decentralised Trial Design: Overcoming the Hidden Obstacles	11:00 - 13:00
FIT-PH/ UK Cohort study w- Deciphering the rosetta stone of digital endpoints Mark Toshner & Alex Rothman	11:00 - 11:15
Panel discussion & debate	11:15 - 11:40
Stratified & adaptive trial designs Introduction: Mardi Gomberg-Maitland	11:40 - 11:55
Bayesian approaches Sofia Villar	11:55 - 12:10
Putting the physician in the corner: the patient-centred Trial Joanna Pepke-Zaba	12:10 - 12:25
Panel Discussion & Debate	12:25 - 13:00
Lunch	13:00 - 14:00





10 July Day 1 Session 2

14:00 - 17:00

Lessons Learned from Clinical Trials in PH Groups 2 & 3: What are the Similarities & Differences in Pathogenesis & Pathophysiology?

Chairs: Mardi Gomberg- Maitland & Steven Nathan
Panellists: TBD & Sylvia Nikkho

PH Group 2

Pathophysiology & pathogenesis Introduction: Ray Benza	14:00 - 14:20
In adults Ray Benza	14:20 - 14:40
In paediatric Rachel Hopper	14:40 - 15:00
Panel discussion & debate	15:00 - 15:30

PH-Group 3

Pathophysiology & pathogenesis Introduction: Paul Hassoun	15:30 - 15:50
In adults Steven Nathan	15:50 - 16:10
In paediatrics Steven Abman	16:10 - 16:30
Panel discussion & debate	16:30 - 17:00

Drinks Reception

17:00 19:00





11 July Day 2 Session 3

08:30 - 13:30

Novel Drug & Device Therapies	08:30 - 10:00
Chairs: Anna Hemnes & Ray Benza Panellists: Steph Hopley, Carol Satler & Hunter Gillies	
Abstract 22 patients John Scandurra	08:30 - 08:40
Targeting HDAC inhibition for pulmonary hypertension Bjorn Dahlof	08:40 - 08:55
Discussion	08:55 - 09:00
TGF- β ligands for pulmonary arterial hypertension Simon Cooper	09:00 - 09:15
Discussion	09:15 - 09:20
Targeting the zinc transporter, ZIP12, with a monoclonal antibody Lan Zhao	09:20 - 09:35
Discussion	09:35 - 09:40
Debate & wash up	09:40 - 09:55
How do we Design the Trials? Nick Hill	09:55 - 10:45

Break

10:45 - 11:10

Disruptive Technologies in Novel Drug Discovery	11:10 - 12:30
Using large data aggregates Steven Kawut	11:10 - 11:30
Molecular clustering Allan Lawrie	11:30 - 11:50
Imaging & the lung Alex Dusek & Ben Lavon	11:50 - 12:10
Debate & discussion	12:10 - 12:30
Roundtable: Practicle Solutions to Challenges in Drug Development	12:30 - 13:30
Chairs: Mark Toshner, Sylvia Nikkho, Ray Benza & Peter Fernandes	
Highlight 10 challenges & vote on the top 3 & solve them	

End of Meeting

